Some insight into Pfizer's M&A strategy: Tidy up your labs,...

Some insight into Pfizer's M&A strategy:

Tidy up your labs, biotech. Pfizer is coming with 'significant firepower' and cash to burn
Dec 13, 2021 11:22am
https://www.fiercebiotech.com/biote...coming-significant-firepower-and-cash-to-burn

Pertinent extracts from this article:

"...the company has set two priorities for future acquisitions: compelling later-stage assets that can provide revenue in the back half of the decade and potential medical breakthroughs in earlier-stage development."

"The company has “significant firepower” to engage in M&A and plans “to be very active in dealmaking,” Malik said."

"Pfizer’s revenue is expected to reach $101.3 billion in 2022, thanks to the BioNTech-partnered COVID-19 vaccine and an antiviral, Paxlovid, that has posted strong data. Comirnaty alone is expected to bring in $29.7 billion next year, according to recent analyst projections."

"We like the risk of earlier-stage deals where we know not all of them will work out, but the scope for what we can do to add value is significant,” Malik said."

"Besides external M&A, Pfizer will also look to add any data and technology that can help accelerate its delivery of medicines and bring value to patients.
'We will use business development to bolster our pipeline with targeted investments that we believe will be fundamental breakthroughs to bring in more and better substrate to Pfizer,' Malik said."